It is, therefore, unclear whether, in a HER2-positive breast cancer subtype scheme, such a therapeutic combination will be effective in different scenarios characterised by small molecular variations, this despite previously published reports in the scientific literature. The gene discussed is ERBB2; the disease is breast cancer.